Dantari
Biotech firm specializing in developing pharmaceuticals for central nervous system treatments.
Founded
2018Biotech firm specializing in developing pharmaceuticals for central nervous system treatments.
Dantari, founded with a mission to revolutionize treatments for the central nervous system, is a pharmaceutical biotechnology company focused on developing advanced drug conjugates. Their core vision is to create innovative therapies that significantly improve patient outcomes, particularly for those suffering from severe and challenging conditions. Dantari offers a specialized pharmaceutical platform aimed at treating central nervous system disorders and has expanded its focus to include targeted medicines for solid tumors.
Notable figures associated with Dantari include Steve Shoffner, who has been prominently featured in company news. The company secured significant Series A financing led by Westlake Village BioPartners, with additional participation from other investors. Among its key achievements, Dantari's novel high-capacity drug conjugate, DAN-, has shown promising antitumor activity in patients with metastatic HER2-negative breast cancer during Phase clinical trials. This breakthrough underscores Dantari's impact on advancing best-in-class targeted medicines and improving therapeutic options for patients with severe illnesses.
Companies similar to Dantari include NantBio, Cantai Therapeutics, Valiant DTX and WinSanTor.
Dantari was founded in 2018.
Dantari's headquarters is located in Thousand Oaks, CA, US.
Dantari's most recent funding round was for $47M (USD) in December 2022.
As of Dec 8, 2022, Dantari has disclosed funding of $47M (USD). Undisclosed round amounts are excluded.
Dantari has 14 employees as of Feb 4, 2024.
